398 ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia
519 Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
151 Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study
512 Cooperative Targeting of Bcl-2 Family Proteins By ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells
And a few other articles, these arent from ASH, but worth a look:
(Now this in theory sounds great, maybe we can see an individual TKI dose adjustment for most effect and least side effects)
- ABT-199 in combo with TKI might actually , dare i say it, cure us, and also help treat BC CML. (Lets hope this one works out)
- A new drug ( ABL001) being tested that works on most mutations, including T315 (in combo with Nilotinib)
- Ponatinib seems like a very potent drug (as we already knew, but i dont mind reading about it again), lets hope they can tweak the dosage right in regards to serious side effects.
- One thing that interested me from the EURO-SKI study was this:
Recurrence of CML, defined as loss of MMR, was observed in 43/92 pts (47%) treated <8 years, as compared to 23/87 pts (26%) treated for >8 years (p= 0.005). So far, there was a trend for prognostic significance of MR4 duration: 33/71 pts with MR4 <5 years (46%) lost MMR within 6 mo as compared to 28/87 pts (32%) with MR4duration >5 years (p=0.07).
No significant difference was observed for relapse within 6 mo according to depth of molecular response at discontinuation (MR4 vs MR4.5 vs MR5). "
"TKI cessation was a safe procedure but a substantial proportion of pts reported transitory musculoskeletal pain starting within weeks after imatinib discontinuation. The phenomenon was described in 30% of Swedish patients as a "TKI withdrawal syndrome" (Richter JCO 2014). "
So patients who have been < MR 4 longer than 5-8 years, have a much better chance of not having the CML return, and it doesnt seem to matter if you are MR 4 or PCRU?
Also, "TKI withdrawal syndrome" does not sound particilary fun. Maybe its just the swedes that get it
Maybe my thoughts on this are wrong, please correct me if so, it feels pretty exciting to be reading about all this, and it gives me hope of a bright future, to bad i cant understand it all as im a not a Doctor, nor do i have the insights of some of the people on this forum
PS: The part of about the swedes was of course intended as a bit of a joke, i hope noone gets offended.